Health
CVS CEO defends pharmacy middlemen, accuses drugmakers of ‘monopolistic’ practices
David Joyner, a longtime CVS executive, speaks during a Senate Health, Education, Labor and Pensions Committee hearing in Washington, D.C., on May 10, 2023. Al Drago | Bloomberg | Getty Images CVS Health CEO David Joyner on Wednesday defended controversial pharmacy middlemen like his company’s Caremark unit, which are widely accused of inflating prescription medication […]
Read More
Apple launches first major health study in 5 years. Here’s how you can opt in
Apple CEO Tim Cook delivers remarks before the start of an Apple event at the Apple headquarters in Cupertino, California, on Sept. 9, 2024. Justin Sullivan | Getty Images Apple is deepening its investment in health-care research by launching a new, years-long project called the Apple Health Study, the company announced on Wednesday. The study […]
Read More
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer’s treatment Leqembi, saw growth. But the biotech company’s […]
Read More
CVS results top estimates even as high medical costs drag down insurance unit
An exterior view of a CVS pharmacy in Danville, Pennsylvania. Paul Weaver | Lightrocket | Getty Images CVS Health on Wednesday reported fourth-quarter revenue and profit that topped estimates, even as its troubled insurance business continued to see higher medical costs. The company also issued a full-year 2025 adjusted earnings outlook of $5.75 to $6 […]
Read More
We’re adding to our position in a sliding stock and booking profits in a 2025 winner
We’re making a pair of trades Monday as Wall Street rallies to kick off the week. Source
Read More
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading’ patients
Hims & Hers is facing scrutiny from lawmakers over an advertisement for its weight loss offerings that’s slated to run during the Super Bowl on Sunday. Sens. Dick Durbin, D-Ill., and Roger Marshall, R-Kan., wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an “upcoming advertisement” that “risks misleading […]
Read More
Doximity shares pop 30% on revenue beat, rosy guidance
Piotr Swat | Lightrocket | Getty Images Doximity shares ripped more than 30% higher on Friday, a day after the company reported fiscal third-quarter results that beat Wall Street’s expectations for revenue and guidance. Doximity is a digital platform for medical professionals that can help them carry out telehealth appointments with patients, find referrals, stay […]
Read More
Alphabet’s Verily to sell Granular insurance business to Elevance Health
Verily headquarters in San Bruno, California. Courtesy: Verily Verily is selling its stop-loss insurance subsidiary, Granular Insurance Company, to the insurance provider Elevance Health, the Alphabet health tech company confirmed to CNBC on Thursday. Verily is one of Google’s sister companies and operates within Alphabet’s “Other Bets” category. The Granular sale is the latest in […]
Read More
Bristol Myers’ stock decline in response to weak guidance is a gift to investors
Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]
Read More